Renaissance Group’s Indivior Pharmaceuticals INDV Stock Holding History

Renaissance Group’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-130,529	Closed	-$2.1M	–	247
2024 Q2	$2.1M	Buy	130,529 +2,351	+2%	+$42.4K	0.08%	192
2024 Q1	$2.75M	Buy	128,178 +25,155	+24%	+$473K	0.1%	155
2023 Q4	$1.57M	Buy	103,023 +5,896	+6%	+$105K	0.07%	188
2023 Q3	$2.24M	Buy	97,127 +1,959	+2%	+$44.7K	0.1%	130
2023 Q2	$2.26M	Buy	+95,168	New	+$2.18M	0.1%	128

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

LIP

Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return

Renaissance Group's INDV Position: Q3 2024 in Review

Renaissance Group sold out of Indivior Pharmaceuticals (INDV) in Q3 2024, closing a stake of 130,529 shares — an estimated $2.1M sold.

Renaissance Group first reported a position in INDV in Q2 2023 and held it in 5 quarters. The position peaked at $2.75M in Q1 2024. 103 funds tracked by Wall St. Rank hold INDV as of Q3 2024.

Renaissance Group reported no remaining Indivior Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Renaissance Group sold 130,529 Indivior Pharmaceuticals shares in Q3 2024, an estimated $2.1M.
Renaissance Group first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 5 quarters.
Renaissance Group's Indivior Pharmaceuticals position peaked at $2.75M in Q1 2024.
103 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2024.

Based on Renaissance Group's 13F filing for Q3 2024, filed 12 Nov 2024.